The Problem: The Hidden Shield

PD-1/L1 molecules have been launched for over 10 years,
yet 80% of patients still fail to achieve durable clinical benefit.

The limiting factor is no longer the molecule's efficacy;
It is the host's CRP-MDSC axis suppressing immune response.

The Scientific Grounding:
CRP as the Constraint

A 2023 multicenter study published in the Journal for ImmunoTherapy of Cancer (JITC) analyzed 1,036 patients across multiple cancer types treated with immune checkpoint inhibitors.

The findings were striking:
Patients with persistently high CRP showed an objective response rate of only 12%, a median progression-free survival of 2.3 months, and a median overall survival of 8.1 months.

Patients with consistently normal CRP showed an objective response rate of 41%, a median progression-free survival of 8.2 months, and a median overall survival of 24.5 months.
This pattern held across cancer types — lung, kidney, bladder, melanoma, and others — suggesting CRP is not a tumor-specific marker,
but a systemic constraint on immune response.

The implication: CRP is not merely a biomarker. It is a ceiling on what PD-1 therapy can deliver.
Read the full study →

The Solution:
CMB → CRP-MDSC Blocker

Independent GLP-validated data (C57BL/6 + MC38 model) demonstrates:

• >50% tumor reduction compared to PD-1 alone
• Zero additive chemo-like side effects

We are advancing a 1-year Investigator-Initiated Study (IIS)
to generate rapid human proof-of-concept.